{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.6","value":"40800"},{"groupId":"OG001","spread":"40.0","value":"34600"},{"groupId":"OG002","spread":"90.8","value":"975000"},{"groupId":"OG003","spread":"70.4","value":"1280000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.8","value":"42300"},{"groupId":"OG001","spread":"74.7","value":"45600"},{"groupId":"OG002","spread":"62.5","value":"1510000"},{"groupId":"OG003","spread":"56.3","value":"1650000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received modakafusp alfa 0.4 mg/kg infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG000","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa 0.4 mg/kg"},{"description":"Participants received modakafusp alfa 0.4 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG001","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa 0.4 mg/kg + Dexamethasone 40 mg"},{"description":"Participants received modakafusp alfa 1.5 mg/kg infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG002","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa 1.5 mg/kg"},{"description":"Participants received modakafusp alfa 1.5 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG003","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa 1.5 mg/kg + Dexamethasone 40 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK Analysis Set included participants from the SAS who had sufficient data to calculate at least 1 PK parameter for modakafusp alfa. Overall number of participants analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis during the specified time-point.","reportingStatus":"POSTED","timeFrame":"Schedule C and D: Pre-infusion and at multiple times post-infusion on Day 1 of Cycles 1 and 2: (cycle length was 21 days for Schedule C and 28 days for Schedule D)","title":"Part 2: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Modakafusp Alfa","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}